Karyopharm Therapeutics (KPTI) Work In Process (2020 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Work In Process came in at $3.0 million in Q4 2025, down 15.87% YoY from $3.5 million in Q4 2024, and up 2.65% on a QoQ basis from $2.9 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Work In Process (2020 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 6 years of Work In Process data on file, last reported at $3.0 million in Q4 2025.
- Quarterly Work In Process fell 15.87% year-over-year to $3.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.0 million (down 15.87% YoY) and the FY2025 annual result came in at $3.0 million, down 15.87% from the prior year.
- Work In Process grew to $3.0 million in Q4 2025, from $2.9 million in the prior quarter.
- In the past five years, Work In Process ranged from a high of $4.2 million in Q2 2025 to a low of $781000.0 in Q1 2021.
- A 5-year average of $2.3 million and a median of $1.9 million in 2021 frame the typical range for Work In Process.
- Annual changes were most pronounced in 2021 — Work In Process jumped 193.34% — and 2023, when it plunged 40.68%.
- Tracing KPTI's Work In Process over 5 years: stood at $1.9 million in 2021, then decreased by 0.9% to $1.9 million in 2022, then fell by 7.77% to $1.7 million in 2023, then jumped by 104.5% to $3.5 million in 2024, then declined by 15.87% to $3.0 million in 2025.
- The last three Work In Process figures came in at $3.0 million (Q4 2025), $2.9 million (Q3 2025), and $4.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.17 Mn |
| Dec 31, 2025 | 2.98 Mn |
| Sep 30, 2025 | 2.90 Mn |
| Jun 30, 2025 | 4.17 Mn |
| Mar 31, 2025 | 3.91 Mn |
| Dec 31, 2024 | 3.54 Mn |
| Sep 30, 2024 | 3.41 Mn |
| Jun 30, 2024 | 2.16 Mn |
| Mar 31, 2024 | 1.59 Mn |
| Dec 31, 2023 | 1.73 Mn |
| Sep 30, 2023 | 1.96 Mn |
| Jun 30, 2023 | 1.70 Mn |
| Mar 31, 2023 | 1.77 Mn |
| Dec 31, 2022 | 1.88 Mn |
| Sep 30, 2022 | 3.00 Mn |
| Jun 30, 2022 | 2.87 Mn |
| Mar 31, 2022 | 926,000.00 |
| Dec 31, 2021 | 1.90 Mn |
| Sep 30, 2021 | 1.83 Mn |
| Jun 30, 2021 | 1.86 Mn |